These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 36685525)
1. A high interferon gamma signature of CD8 Li S; Li K; Tian F; Li H; Xia Q; Li T; Dong B; Li D; Yu J; Zhang J; Wang L; Zhang C; Xu S; Zhao Y; Liu Y Front Immunol; 2022; 13():1056144. PubMed ID: 36685525 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells. He Y; Yang D; Lin X; Zhang J; Cheng R; Cao L; Yang L; Zhang M; Shi X; Jin X; Sun H; Sun H; Zang J; Li Y; Ma J; Nie H Front Immunol; 2024; 15():1412693. PubMed ID: 39076970 [TBL] [Abstract][Full Text] [Related]
3. Development of a CD8+ T cell associated signature for predicting the prognosis and immunological characteristics of gastric cancer by integrating single-cell and bulk RNA-sequencing. Li J; Han T; Wang X; Wang Y; Yang R; Yang Q Sci Rep; 2024 Feb; 14(1):4524. PubMed ID: 38402299 [TBL] [Abstract][Full Text] [Related]
4. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis. Xing X; Shi J; Jia Y; Dou Y; Li Z; Dong B; Guo T; Cheng X; Li X; Du H; Hu Y; Jia S; Zhang J; Li Z; Ji J J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361730 [TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer. Duan R; Li X; Zeng D; Chen X; Shen B; Zhu D; Zhu L; Yu Y; Wang D Front Immunol; 2020; 11():609337. PubMed ID: 33569057 [TBL] [Abstract][Full Text] [Related]
7. Progenitor-like exhausted SPRY1 Liu Z; Zhang Y; Ma N; Yang Y; Ma Y; Wang F; Wang Y; Wei J; Chen H; Tartarone A; Velotta JB; Dayyani F; Gabriel E; Wakefield CJ; Kidane B; Carbonelli C; Long L; Liu Z; Su J; Li Z Cancer Cell; 2023 Nov; 41(11):1852-1870.e9. PubMed ID: 37832554 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. Tang X; Li M; Wu X; Guo T; Zhang L; Tang L; Jia F; Hu Y; Zhang Y; Xing X; Shan F; Gao X; Li Z Oncoimmunology; 2022; 11(1):2135819. PubMed ID: 36268179 [TBL] [Abstract][Full Text] [Related]
9. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108 [TBL] [Abstract][Full Text] [Related]
11. Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. Wang JB; Qiu QZ; Zheng QL; Zhao YJ; Xu Y; Zhang T; Wang SH; Wang Q; Jin QW; Ye YH; Li P; Xie JW; Lin JX; Lu J; Chen QY; Cao LL; Yang YH; Zheng CH; Huang CM Adv Sci (Weinh); 2023 May; 10(15):e2207417. PubMed ID: 36998102 [TBL] [Abstract][Full Text] [Related]
12. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235 [TBL] [Abstract][Full Text] [Related]
13. MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response. Zhang B; Wang CM; Wu HX; Wang F; Chai YY; Hu Y; Wang BJ; Yu Z; Xia RH; Xu RH; Cao XT Cancer Commun (Lond); 2023 Oct; 43(10):1097-1116. PubMed ID: 37539769 [TBL] [Abstract][Full Text] [Related]
14. Strategies to reinvigorate exhausted CD8 Guan Q; Han M; Guo Q; Yan F; Wang M; Ning Q; Xi D Front Immunol; 2023; 14():1204363. PubMed ID: 37398660 [TBL] [Abstract][Full Text] [Related]
15. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683 [TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer. Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797 [TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer. Lin Y; Jing X; Chen Z; Pan X; Xu D; Yu X; Zhong F; Zhao L; Yang C; Wang B; Wang S; Ye Y; Shen Z Theranostics; 2023; 13(13):4574-4600. PubMed ID: 37649598 [No Abstract] [Full Text] [Related]
18. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer. Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487 [TBL] [Abstract][Full Text] [Related]
19. 9-Gene Signature Correlated With CD8 Yan K; Lu Y; Yan Z; Wang Y Front Immunol; 2021; 12():622563. PubMed ID: 34220795 [TBL] [Abstract][Full Text] [Related]
20. PES1 reduces CD8 Ma N; Hua R; Yang Y; Liu ZC; Pan J; Yu BY; Sun YF; Xie D; Wang Y; Li ZG J Biomed Sci; 2023 Mar; 30(1):20. PubMed ID: 36959575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]